



中山醫學大學附設醫院

肝癌診療指引

本臨床指引參考AASLD、APASL、EASL與美國NCCN版本

再依據中山醫學大學附設醫院肝癌小組經驗作編修

肝癌多專科醫療團隊編修

2025/11/26 Version19.0
2024/11/20 Version18.0
2023/11/15 Version17.0
2022/12/07 Version16.0
2021/11/17 Version15.0
2020/12/16 Version14.0
2019/11/20 Version13.0
2018/09/12 Version12.0
2017/11/22 Version11.0
2016/12/14 Version10.0
2015/11/25 Version9.0
2014/12/10 Version8.0
2013/12/25 Version7.0
2012/12/12 Version6.0
2011/12/14 Version5.1
2011/03/22 Version5.0
2010/02/11 Version4.0
2009/12/17 Version3.0
2008/11/14 Version2.0
2007/10/11 Version1.0

癌症委員會主任委員	癌症委員會執行長	癌症中心主任	抗癌藥物安全小組	團隊負責人
詹堯川		趙政	黃偉明	張明學

修訂內容

頁數	第 18 版	第 19 版												
P1	<p>一、前言</p> <p>1.根據衛生福利部112死因統計年報：肝癌為國人主要癌症死因第二位，標準化死亡率為每十萬人口有33.1。男性肝癌標準化死亡率為每十萬人口45.6，女性肝癌標準化死亡率為每十萬人口20.9。</p>	<p>一、前言</p> <p>1.根據衛生福利部113年死因統計年報：肝癌為國人主要癌症死因第二位，標準化死亡率為每十萬人口有32.1人。男性肝癌標準化死亡率為每十萬人口44.0人，女性肝癌標準化死亡率為每十萬人口20.5人。</p>												
P17-18	<p>六、放射線治療</p> <p>1.適用對象:放射線治療適應症包括不能開刀、肝門靜脈阻塞、或者轉移的病人。</p> <p>2.治療方式包括 3D-CRT, IMRT, Arc therapy, Tomotherapy 以及 SBRT</p> <p>3.肝癌患者做放射線治療前應評估 Child-Pugh score</p> <p>(1)立體定位放射治療(SBRT)：</p> <p>A..病人的選擇：prefer Child A~B patients</p> <p>B.劑量和次數：30~50Gy/3~5fxs</p> <p>4.肝門靜脈阻塞建議劑量：50~65Gy</p>	<p>六、放射線治療</p> <p>1. 放射線治療適應症包括：</p> <p>A 不能開刀、不適合 RFA 或血管栓塞或者以上治療後失敗、復發的病人。</p> <p>B 肝門靜脈阻塞或其他如轉移性腫瘤、tumor bleeding 等緩和性治療。</p> <p>C 肝癌引致各處轉移，放射治療可緩解症狀或控制疾病。</p> <p>2. 治療方式包-CRT, IMRT, Arc therapy, TomoTherapy, Rdiact 以及 SBRT (建議搭配呼吸調控技術或 4D-CT simulation 或 tumor tracking 等)</p> <p>3. 肝癌患者做放射線治療前應評估 Child-Pugh score 及 ECOG status</p> <p>4. 劑量建議</p> <table border="1"> <thead> <tr> <th>Regimen[☐]</th> <th>Dose[☐]</th> <th>Notes[☐]</th> </tr> </thead> <tbody> <tr> <td>**SBRT[☐]</td> <td>40–60 Gy in 3–5 fractions[☐]</td> <td>Preferred if dose constraints met[☐]</td> </tr> <tr> <td>Hypofractionation[☐]</td> <td>37.5–72 Gy in 10–15 fractions[☐]</td> <td>Acceptable alternative[☐]</td> </tr> <tr> <td>Conventional fractionation[☐]</td> <td>50–66 Gy in 25–33 fractions[☐]</td> <td>For patients unsuitable for SBRT[☐]</td> </tr> </tbody> </table> <p>**SBRT 健保給付條件 (需事先送審)：</p> <p>1. 原發性肝膽單一病灶 (可為原發性肝癌或肝內膽道癌，同時無肝外淋巴侵犯和遠端轉移)，肝功能為 Child-Pugh A 至 B 級，ECOG status ≤ 2 (或 Karnofsky Performance Scale/KPS ≥ 70)，病灶最大徑 ≤ 5 公分。且經評估無法進行下列之一的治療或下列之一的治療失敗者 (依病歷紀錄)：A. 手術切除，B. 血管栓塞治療，C. 電燒灼治療。</p> <p>2. 需經外科醫師會診，麻醉科醫師評估不適合接受治療性術式切除者 (附病歷紀錄) 或多專科團隊討論會之結論認為不適合接受治療性術式切除者 (附會議紀錄)。Constraints for organ at risk Normal organ dose responses from the QUANTEC project.</p>	Regimen [☐]	Dose [☐]	Notes [☐]	**SBRT [☐]	40–60 Gy in 3–5 fractions [☐]	Preferred if dose constraints met [☐]	Hypofractionation [☐]	37.5–72 Gy in 10–15 fractions [☐]	Acceptable alternative [☐]	Conventional fractionation [☐]	50–66 Gy in 25–33 fractions [☐]	For patients unsuitable for SBRT [☐]
Regimen [☐]	Dose [☐]	Notes [☐]												
**SBRT [☐]	40–60 Gy in 3–5 fractions [☐]	Preferred if dose constraints met [☐]												
Hypofractionation [☐]	37.5–72 Gy in 10–15 fractions [☐]	Acceptable alternative [☐]												
Conventional fractionation [☐]	50–66 Gy in 25–33 fractions [☐]	For patients unsuitable for SBRT [☐]												

P19-22

七、標靶藥物治療

藥名	使用順序	給藥途徑	建議劑量	適用條件	健保
Sorafenib (Nexavar)	第一線	口服	400mg/day	(1)轉移性或無法手術切除且不符合局部治療或局部治療失敗之晚期肝癌患者，並符合下列條件之一： A.肝外轉移（遠端轉移或肝外淋巴結侵犯）的 Child-Pugh A class 患者。 B.大血管侵犯（腫瘤侵犯主門靜脈或侵犯左/右靜脈第一分支）的 Child-Pugh A class 患者。 C.經導管動脈化學藥物栓塞治療（T.A.C.E）失敗之晚期肝癌患者。 Child-Pugh A class 患者，需提供患者於 12 個月內≥3 次局部治療之記錄。 (2)需經事前審查核准後使用，初次申請之療程以 3 個月為限，之後每 2 個月評估一次。送審時需檢送影像資料，無疾病惡化方可繼續使用。	給付
Lenvatinib (Lenvima)	第一線	口服	12 mg/day	(1)轉移性或無法手術切除且不符合局部治療或局部治療失敗之 Child-Pugh A 晚期肝癌患者。 (2)需經事前審查核准後使用，初次申請之療程以 3 個月為限，之後每 2 個月評估一次。送審時需檢送影像資料，無疾病惡化方可繼續使用。 (3)Lenvatinib 與 sorafenib 僅得擇一使用，不得互換；且 lenvatinib 治療失敗後，不得申請使用 Sivarga 或 Opdivo。(109/11)	給付

藥名	使用順序	給藥途徑	建議劑量	適用條件	健保
Bevacizumab (Avastin)	第一線	靜脈注射	500mg/次 (每三週一次)	(1)未曾接受全身性療法且無法切除或轉移肝癌患者，且肝功能為 Child-Pugh A。 (2)建議與 Atezolizumab(Tecentriq)搭配使用。	給付
Regorafenib (Stivarga)	第二線	口服	160 mg/day	(1)適用於曾接受 sorafenib 治療失敗後之轉移性或無法手術切除且不符合局部治療或局部治療失敗之 Child-Pugh A class 晚期肝癌患者。 (2)需經事前審查核准後使用，初次申請之療程以 3 個月為限，之後每 2 個月評估一次。送審時需檢送影像資料，無疾病惡化方可繼續使用。	給付
Cabometyx (Cabozantinib)	第二線	口服	60mg/day	(1)適用於曾接受 sorafenib 治療失敗後之轉移性或無法手術切除且不符合局部治療或局部治療失敗之 Child-Pugh A class 晚期肝癌患者。 (2)Child-Pugh B 患者建議每日建議劑量為 40mg/day。	未給付
Ramucirumab (Cyramza)	第二線	靜脈注射	8 mg/kg (每三週一次)	(1)單一療法適用於接受過 sorafenib 治療失敗後之轉移性或無法手術切除且不符合局部治療或局部治療失敗，且 AFP≥ 400ng/mL 之 Child-Pugh A class 晚期肝癌患者。 (2)需經事前審查核准後使用，初次申請之療程以 12 週為限，之後每 8 週評估一次。送審時需檢送影像資料，無疾病惡化方可繼續使用。 (3)Ramucirumab 與 regorafenib、nivolumab 僅能擇一使用，不得互換。	給付

七、Advanced&Metastatic radiation

第一線用藥

Sorafenib

Sorafenib(Nexavar) 200mg/tab po QD 400- 800mg /day

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.

Lenvatinib

Lenvatinib(Lenvima) 4 mg/cap po QD 8-12mg/day

備註：依病患腎功能調整劑量
Kudo M, Finn R S, Qin S, Han K H, Ikeda K, Piscaglia F, et al. (2018). Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. The Lancet, 391(10126), 1163–1173.

Atezolizumab+Bevacizumab

Atezolizumab(Tecentriq) 1200 mg IV over 60 min every 3 weeks

Bevacizumab(Avastin) 15mg/kg IV over 60 min every 3 weeks

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. *The New England Journal of Medicine*, 359(4), 378–390.

Tremelimumab+ Imfinzi

Tremelimumab 300mg IV over 60 min(僅第一次療程)

Imfinzi 1500 mg IV over 60 min every 4 weeks

Llovet, J. M., et al. (2021). Hepatocellular carcinoma. *Nature Reviews Disease Primers*, 7, 6.
IMJUDO (tremelimumab-act) [Prescribing information]. (2022). U.S. Food and Drug Administration.
IMFINZI (durvalumab) [Prescribing information]. (2022). U.S. Food and Drug Administration.

第二線用藥

Regorafenib

Regorafenib(Stivarga) 40mg/tab po QD 40-160mg /day

Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., Gerolami, R., Masi, G., Ross, P. J., Song, T., Bronowicki, J.-P., Olivier-Houmand, I., Kudo, M., Cheng, A. L., Llovet, J. M., ... Han, G. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*, 389(10064).

56-66. [https://doi.org/10.1016/S0140-6736\(16\)32453-9](https://doi.org/10.1016/S0140-6736(16)32453-9)

Cabometyx

Cabometyx(Cabozantinib) 40mg/tab po QD 60mg /day

Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., Rimassa, L., Sen, S., Milwee, S., El-Khoueiry, A. B. (2022). Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomized controlled trial. *BMC Cancer*, 22, 377



八、免疫治療

藥名	使用順序	給藥途徑	建議劑量	適用條件	健保
Atezolizumab (Tecentriq)	第一線	靜脈注射	1200mg/次 (每三週一次)	(1)未曾接受全身性療法且無法切除或是轉移肝癌細胞癌病人，肝功能為 Child-Pugh A。 (2)建議與 Bevacizumab 15mg/kg 搭配使用。	給付
Imfinzi (Durvalumab)	第一線	靜脈注射	1200mg/次 (每四週一次)	(1)未曾接受全身性療法且無法切除或是轉移肝癌細胞癌病人，肝功能為 Child-Pugh A。	未給付
Nivolumab (OPDIVO)	第二線	靜脈注射	3 mg/kg (每二週一次)	(1)適用對象:晚期肝癌細胞癌。	未給付
Pembrolizumab (Keytruda)	第二線	靜脈注射	2 mg/kg (每三週一次)	(1)適用對象:晚期肝癌細胞癌。	未給付
Ipilimumab (Yervoy)	第二線	靜脈注射	3 mg/kg (每三週一次)	(1)晚期肝癌細胞癌，且肝功能為 Child-Pugh A。 (2)建議與 Nivolumab 3mg/kg 搭配使用。	未給付

Ipilimumab + Nivolumab

Ipilimumab (Yervoy) 1-3mg/kg	IV over 60 min every 3 weeks
Nivolumab (OPDIVO)1- 3 mg/kg	IV over 60 min every 3 weeks

備註: Ipilimumab (Yervoy) 每隔 3 週給藥一次，總共投予 4 劑。

Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., Pinter, M., Peña, A. M., Ikeda, M., Tai, D., Santoro, A., Pizarro, G., Chiu, C.-F., Schenker, M., He, A., Chon, H. J., ... Kudo, M. (2025). Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial. *The Lancet. Advance online publication.*

Nivolumab

Nivolumab (OPDIVO)1- 3 mg/kg	IV over 60 min every 2weeks
------------------------------	-----------------------------

Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., Pinter, M., Peña, A. M., Ikeda, M., Tai, D., Santoro, A., Pizarro, G., Chiu, C.-F., Schenker, M., He, A., Chon, H. J., ... Kudo, M. (2025). Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial. *The Lancet. Advance online publication.*

Ramucirumab

Ramucirumab(Cyramza) 8 mg/kg	IV over 30 min every 3weeks
------------------------------	-----------------------------

Zhu, A. X., Kang, Y. K., Yen, C. J., Finn, R. S., Galle, P. R., Llovet, J. M., et al. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*, 20(2), 282–296.

Pembrolizumab

Pembrolizumab(Keytruda) 2 mg/kg	IV over 60 min every 3weeks
---------------------------------	-----------------------------

Zhu AX, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224). *Lancet Oncology*. 2018;19(7):940–952.

目錄

一、前言.....	P 1
二、組織病理分期與分化.....	P 2
三、肝癌分期.....	P 3
四、肝癌診斷.....	P 6
五、肝癌治療.....	P 7
六、放射線治療.....	P 17
七、Advanced&Metastatic radiation.....	P 19
八、安寧緩和照護原則.....	P 22
九、完治率定義.....	P 23
十、參考文獻.....	P24

一、前言

1. 根據衛生福利部113年死因統計年報：肝癌為國人主要癌症死因第二位，標準化死亡率為每十萬人口有32.1人。男性肝癌標準化死亡率為每十萬人口44.0人，女性肝癌標準化死亡率為每十萬人口20.5人。
2. 本院肝癌診斷流程的建立，係參考2010年AASLD，期以提高肝癌診斷證實率與準確性。
3. 本院肝癌分期採用美國TNM與歐洲BCLC二大癌症分期系統並行，後者除了考慮腫瘤大小因素外
4. 亦加入肝功能指標，以符合臨床科的需求。
5. 本院肝癌治療指引係多專科醫療團隊的整合，治療流程以實證醫學並參考國內外醫學中心治療指引，期以提高肝癌病人生活品質。



二、組織病理分期與分化

肝癌以肝細胞癌(hepatocellular carcinoma)為主，本指引對本院較為常見臨床肝癌加以論述。
癌的病理組織分化分為：

分化良好	(grade 1)
分化中度	(grade 2)
分化不良或未分化	(grade 3)
分化無法評估	(grade 4)



三、肝癌分期

(1) Barcelona Clinic Liver Cancer (BCLC)分期

Stage		PST	Tumor Status	Liver Function Status
			Tumor Stage	
Stage 0 : Very early	0	0-1	Single, ≤ 2 cm	Serum bilirubin (WNL) or Child A
Stage A : Early	A	0-1	Single, ≤ 5 cm 3 tumors and < 3 cm	Serum bilirubin (WNL) or Child A~B
Stage B : Intermediate		0-1	Single, ≥ 5 cm or multinodulars	Child-Pugh A~B
Stage C : Advanced		0-2	Vascular invasion or extrahepatic spread	Child-Pugh A~B
Stage D : End stage		3-4	Any	Child-Pugh C

Stage 0, A and B : all criteria should be fulfilled

Stage C and D : all least one criteria should be fulfilled



(2)Child-Pugh Score

points	1	2	3
Encephalopathy (grade)	None	1-2	3-4
Ascites	None	Moderate	Severe
Bilirubin-T (mg/dL)	<2.0	2.0~3.0	>3.0
Albumin(g/dL)	>3.5	2.8~3.5	<2.8
PT(sec) prolong INR	<4.0 <1.7	4.0~6.0 1.7-2.3	>6.0 >2.3

*Child-Pugh Score is the sum of 5 items.

Class A : 5~6 points, good operative risk

Class B : 7~9 points, moderate operative risk

Class C : 10~15 points, poor operative risk



(3) Okuda staging system

Stage	肝臟被腫瘤取代的比率		腹水		血清白蛋白		血清總膽紅素	
	+	-	+	-	+	-	+	-
	(>50%)	(<50%)			(<3g/dL)	(>3g/dL)	(>3mg/dL)	(<3mg/dL)
I	四項都沒有出現							
II	四項中出現1~2項							
III	四項中出現3~4項							



(4) 8th AJCC T-N-M 分期

Primary Tumor(T)	
TX	Primary tumor cancer be assessed
T0	No evidence of primary tumor
T1	Solitary tumor $\leq 2\text{cm}$, or $>2\text{cm}$ without vascular invasion
T1a	Solitary tumor $\leq 2\text{cm}$
T1b	Solitary tumor $>2\text{cm}$ without vascular invasion
T2	Solitary tumor $>2\text{cm}$ with vascular invasion , or multiple tumors , none $>5\text{cm}$
T3	Multiple tumors , at least one of which is $>5\text{cm}$
T4	Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein , or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritonem
Regional Lymph Nodes(N)	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Regional lymph nodes metastasis
Distant Metastasis(M)	
M0	No distant metastasis
M1	Distant metastasis

T-N-M Stage Grouping			
IA	T1a	N0	M0
IB	T1b	N0	M0
II	T2	N0	M0
IIIA	T3	N0	M0
IIIB	T4	N0	M0
IVA	Any T	N1	M0
IVB	Any T	Any N	M1


Fibrosis Score(F)	
F0	Fibrosis score 0-4 (no to moderate fibrosis)
F1	Fibrosis score 5-6 (severe fibrosis or cirrhosis)

Histologic Grade(G)	
GX	Grade cannot be assessed
G1	Well differentiated
G2	Moderately differentiated
G3	Poorly differentiated
G4	Undifferentiated



四、肝癌診斷

EASL 2025 年 Diagnosis Guide





五、肝癌治療

1. Liver transplantation.

(1)親屬捐肝之活體肝臟移植條件:成年人或十八歲以上之未成年人已結婚者，得捐贈部分肝臟予其五親等以內之親屬；十八歲以上之未成年人，經其法定代理人之書面同意，得捐贈部分肝臟予其五親等以內之血親。

(2)五等親範圍:1.配偶(應與捐贈者生有子女或結婚二年以上) 2.直系血親卑親屬。3.父母。4.兄弟姊妹。5.祖父母。6.曾祖父母或三親等旁系血親。7.一親等直系姻親。

(3)若要接受屍體捐肝則條件從嚴(單一腫瘤小於或等於 5 公分，或多發生性腫瘤小於或等於 3 顆，且每一顆大小小於或等於3公分)

(4)活肝移植：單一腫瘤 $\leq 6.5\text{cm}$ ；或多發腫瘤 ≤ 3 個，最大直徑 $\leq 4.5\text{cm}$ ，全部腫瘤直徑和 $\leq 8\text{cm}$ 。

2. 外科手術治療

(1)None or controlled ascites

(2)Bilirubin小於2

(3)Child A與ICG $\leq 15\%$ 可行大範圍的肝切除，Child B與ICG $> 15\%$ 時應視病人整體情況，病人與手術醫師討論之後決定



3. Local therapy (PEIT or RFA), relative contraindication :

- (1) Tumor numbers : 多於3個
- (2) Tumor size : > 5 cm ; (≤ 3 cm , 則可考慮取代 Surgery)
- (3) Ascites (massive or uncontrollable)
- (4) Bleeding tendency (platelet < 80000 or prolonged PT > 5 seconds)
- (5) PEIT > 2 cm , 則不建議, 除非 RFA 無法執行.

4. Contraindication to TACE


- (1) Thrombus in the main portal vein (severe)
- (2) Encephalopathy .
- (3) Biliary obstruction .
- (4) Child-Pugh C cirrhosis : lobar or main portal vein thrombus poor candidates for TACE.


5. Relative contraindication to TACE :

- (1) Serum bilirubin > 3 mg/dL.
- (2) Lactate dehydrogenase > 425 units/L.
- (3) Aspartate aminotransferase > 100 units/L .
- (4) Tumor burden involving > 50 percent of the liver .
- (5) Cardiac or renal insufficiency.
- (6) Ascites, recent variceal bleed, or significant thrombocytopenia.



- 6.依病人performance status and liver reserve，由醫師針對實際狀況考量與病患討論後決定，不建議作為常規之治療方式：
- (1)Chemotherapy agents such as doxorubicin(Epirubicin, Mitoxantrone), 5-FU,cisplatin,Etoposide,Gemcitabine(自費)等
 - (2)Oral Agents(自費) such as Thalidomide, UFT....
- 7.Enrolled onto clinical trial as indication and patients' preference：Targeted agents, immune therapy(Nivolumab), gene therapy.
- 8.Makuuchi's criteria
9. Y90-SIRT:不適合手術切除肝臟,體能狀態為 0 - 1，腫瘤主要位於單一器官，沒有明顯感染，肝臟功能正常，沒有腹水或肝臟衰竭的其它症狀。






Positive AFP >100 ng/mL: (Waidely E, Al-Yuobi AR, Bashammakh AS, et al. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection Analyst 2016;141:36-44), or if AFP increases by ≥ 7 ng/mL/month on at least 3 determinations (Arrieta O, Cacho B, Morales-Espinosa D, et al. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer 2007;7:28). Positive AFP should prompt CT or MRI regardless of US results.





HCC 1
HCC without extrahepatic metastasis And Child-Pugh class A or B



FOLLOW-
 Curative(內外科治癒性療法)或 TA(C)E 治療後 3 個月內追蹤影像學 (echo or CT or MRI)，治療後 1 年內追蹤 ≥3 次。
 Curative 或 TA(C)E 治療前 AFP>20ng/ml，治療後 2 個月內→3 個月內追蹤 AFP。AFP 治療前>20ng/ml 的肝癌病人，治療後 1 年內追蹤 ≥3 次。


* Makuuchi's criteria of liver resection
 # PS>2, comorbidity, etc.
 HAIC : Hepatic arterial chemo infusion
 RFA : Radiofrequency Ablation
 TACE : Transcatheter arterial chemoembolization
 PEIT : Percutaneous Ethanol Injection







TLCA HCC treatment guideline 2023





六、放射線治療

1. 放射線治療適應症包括：

A 不能開刀、不適合 RFA 或血管栓塞或者以上治療後失敗、復發的病人。

B 肝門靜脈阻塞或其他如轉移性腫瘤、tumor bleeding 等緩和性治療。

C 肝癌引致各處轉移，放射治療可緩解症狀或控制疾病。

2. 治療方式包-CRT, IMRT, Arc therapy, TomoTherapy, Rdiact 以及 SBRT (建議搭配呼息調控技術或 4D-CT simulation 或 tumor tracking 等)

3. 肝癌患者做放射線治療前應評估 Child-Pugh score 及 ECOG status

4. 劑量建議

Regimen	Dose	Notes
**SBRT	40–60 Gy in 3–5 fractions	Preferred if dose constraints met
Hypofractionation	37.5–72 Gy in 10–15 fractions	Acceptable alternative
Conventional fractionation	50–66 Gy in 25–33 fractions	For patients unsuitable for SBRT



**SBRT 健保給付條件 (需事先送審):

1. 原發性肝膽單一病灶 (可為原發性肝癌或肝內膽道癌，同時無肝外淋巴侵犯和遠端轉移)，肝功能為 Child-Pugh A 至 B 級，ECOG status ≤ 2 (或 Karnofsky Performance Scale/KPS ≥ 70)，病灶最大徑 ≤ 5 公分。且經評估無法進行下列之一的治療或下列之一的治療失敗者 (依病歷紀錄)：A. 手術切除，B. 血管栓塞治療，C. 電燒灼治療。
2. 需經外科醫師會診，麻醉科醫師評估不適合接受治癒性術式切除者(附病歷紀錄) 或多專科團隊討論會之結論認為不適合接受治癒性術式切除者(附會議記錄)。

Constraints for organ at risk Normal organ dose responses from the QUANTEC project.

Reference:

NCCN Clinical Practice Guidelines in Oncology, 2025

Perez and Brady's Principles and Practice of Radiation Oncology, 7th ed, 2018

Eric K. Hansen, Handbook of Evidence-Based Radiation Oncology



七、Advanced/Metastatic regimens

第一線用藥

Sorafenib

Sorafenib(Nexavar) 200mg/tab	po	QD	400- 800mg /day
------------------------------	----	----	-----------------

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359:378-390.

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009;10:25-34.

Lenvatinib

Lenvatinib(Lenvima) 4 mg/cap	po	QD	8-12mg/day
------------------------------	----	----	------------

備註:依病患腎功能調整劑量

Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. *The Lancet*, 391(10126), 1163–1173.

Atezolizumab+Bevacizumab

Atezolizumab(Tecentriq) 1200 mg	IV over 60 min every 3 weeks
Bevacizumab(Avastin) 15mg/kg	IV over 60 min every 3 weeks

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. *The New England Journal of Medicine*, 359(4), 378–390.

**Tremelimumab+ Imfinzi**

Tremelimumab 300mg	IV over 60 min(僅第一次療程)
Imfinzi 1500 mg	IV over 60 min every 4 weeks

Llovet, J. M., et al. (2021). Hepatocellular carcinoma. *Nature Reviews Disease Primers*, 7, 6.
 IMJUDO (tremelimumab-actl) [Prescribing information]. (2022). U.S. Food and Drug Administration.
 IMFINZI (durvalumab) [Prescribing information]. (2022). U.S. Food and Drug Administration.

第二線用藥**Regorafenib**

Regorafenib(Stivarga) 40mg/tab	po QD 40-160mg /day
--------------------------------	---------------------

Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., Gerolami, R., Masi, G., Ross, P. J., Song, T., Bronowicki, J.-P., Ollivier-Hourmand, I., Kudo, M., Cheng, A. L., Llovet, J. M., ... Han, G. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*, 389(10064), 56–66. [https://doi.org/10.1016/S0140-6736\(16\)32453-9](https://doi.org/10.1016/S0140-6736(16)32453-9)

Cabometyx

Cabometyx(Cabozantinib) 40mg/tab	po QD 60mg /day
----------------------------------	-----------------

Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., Rimassa, L., Sen, S., Milwee, S., El-Khoueiry, A. B. (2022). Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomized controlled trial. *BMC Cancer*, 22, 377

**Ipilimumab + Nivolumab**

Ipilimumab (Yervoy) 1-3mg/kg	IV over 60 min every 3 weeks
Nivolumab (OPDIVO)1- 3 mg/kg	IV over 60 min every 3 weeks

備註：Ipilimumab (Yervoy) 每隔 3 週給藥一次，總共投予 4 劑。

Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., Pinter, M., Peña, A. M., Ikeda, M., Tai, D., Santoro, A., Pizarro, G., Chiu, C.-F., Schenker, M., He, A., Chon, H. J., ... Kudo, M. (2025). Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial. *The Lancet*. Advance online publication.

Nivolumab

Nivolumab (OPDIVO)1- 3 mg/kg	IV over 60 min every 2weeks
------------------------------	-----------------------------

Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., Pinter, M., Peña, A. M., Ikeda, M., Tai, D., Santoro, A., Pizarro, G., Chiu, C.-F., Schenker, M., He, A., Chon, H. J., ... Kudo, M. (2025). Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial. *The Lancet*. Advance online publication.

Ramucirumab

Ramucirumab(Cyramza) 8 mg/kg	IV over 30 min every 3weeks
------------------------------	-----------------------------

Zhu, A. X., Kang, Y. K., Yen, C. J., Finn, R. S., Galle, P. R., Llovet, J. M., et al. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*, 20(2), 282–296.



Pembrolizumab

Pembrolizumab(Keytruda) 2 mg/kg

IV over 60 min every 3weeks

Zhu AX, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224).

Lancet Oncology. 2018;19(7):940–952.



八、安寧緩和照護原則

若預期疾病難以治癒時，病人存活期小於 6 個月便適合安寧療護(Pomeranz & Brustman, 2005 ; Waldrop & Rinfrette, 2009) 。若藉由症狀、檢驗數據、及確切的腫瘤診斷，證實臨床上該惡性腫瘤已經廣泛侵犯、或進展快速；功能分數 (Palliative Performance Scale) 低於 70%；拒絕進一步腫瘤治癒性治療，或者在治療之下仍持續惡化者，即可轉介緩和醫療團隊 (彭等, 2006) 。



九、完治率定義

癌別	分期	治療方式	完治率定義
肝癌	第 I 期	OP、RFA、TACE	後續追蹤腹部電腦斷層，報告顯示無轉移或復發，即可算首次治療完成
	第 II 期	TACE	
	第 III 期	Palliative TAE、OP (Tumor bleeding)	治療後完成，即可算首次完成治療
		口服標靶	療程滿 3 個月就可算完成治療(治療中轉安寧，算完成治療)
		口服標靶 R/T	口服標靶服用滿 3 個月及 R/T 療程結束，即可算首次治療完成
		免疫治療	療程滿 3 個月就可算完成治療(治療中轉安寧，算完成治療)
	第 IV 期	TACE 1 次	即可算首次完成治療
		口服標靶+免疫治療	療程滿 3 個月就可算完成治療(治療中轉安寧，算完成治療)
		口服標靶	
		免疫治療	

備註：

肝內膽管癌：

- (1) 第 I 期: 手術後，後續追蹤腹部電腦斷層，報告顯示無轉移或復發，即可算首次治療完成。
- (2) 第 II、III 期: 接受手術及化療療程滿 3 個月就可算完成治療。
- (3) 第 IV 期: palliative C/T 療程滿 3 個月就可算完成治療。



十、參考文獻

- 衛生福利部全國衛生統計資訊網 (Health and National Health Insurance Annual Statistics Information Service)：民國 113 年國人主要死因統計資料
- Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN*. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: Analysis of 5,613 cases from a medical center in southern Taiwan. *Int J Cancer*. 2007 Jun 15;120(12):2650-5.
- Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY, Lu SN* Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. *J Gastroenterol*. 2008;43(2):159-70.
- Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN* The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. *Eur J Cancer*. 2008 May;44(7):1000-6
- Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lu SN* Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. *Liver Int*. 2009 Jan;29(1):74-81.
- Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, Lee CM, Lin CY, Wang CC, Chen TY, Huang YJ, Lu SN* A modified 6th AJCC/UICC/TNM-based Japan Integrated Score may serve as a better staging system for hepatocellular carcinoma patients. *Digestive Liver Dis*. 2009
- Lu SN, Kee KM, Wang JH, Yen YH, Lin CY, Changchien CS*. Staging of hepatocellular carcinoma: learning from survival analyses of a Taiwanese population according to existed staging or scoring systems. *Chang Gung M J*
- Kolligs FT, Hoffmann RT, op den Winkel M, Bruns CJ, Herrmann K, Jakobs TF, Lamerz R, Trumm C, Zech CJ, Wilkowski R, Graeb C. Diagnosis and multimodal therapy for hepatocellular carcinoma. *Z Gastroenterol*. 2010 Feb;48(2):274-88. Epub 2010 Jan 29. Review. German.
- Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. *Med Clin (Barc)*. 2009 Feb 28;132(7):272-87. Epub 2009 Feb 14.
- Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. *Liver Int*. 2009 Jan;29 Suppl 1:148-58.
- Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. *J Hepatol*. 2008;48 Suppl 1:S20-37. Epub 2008 Feb 12.
- De Giorgio M, Fagioli S. Management of hepatocellular carcinoma. *Dig Dis*. 2007;25(3):279-81.
- Kulik LM. Advancements in hepatocellular carcinoma. *Curr Opin Gastroenterol*. 2007 May;23(3):268-74.
- Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. *Oncogene*. 2006 Jun 26;25(27):3848-56.
- Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. *Semin Liver Dis*. 2005;25(2):181-200.



- Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. *Semin Liver Dis.* 2005;25(2):171-80.
- Llovet JM. Updated treatment approach to hepatocellular carcinoma. *J Gastroenterol.* 2005 Mar;40(3):225-35.
- Llovet JM, Sala M. Non-surgical therapies of hepatocellular carcinoma. *Eur J Gastroenterol Hepatol.* 2005 May;17(5):505-13.
- Fuster J, Charco R, Llovet JM, Bruix J, García-Valdecasas JC. Liver transplantation in hepatocellular carcinoma. *Transpl Int.* 2005 Mar;18(3):278-82.
- França AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. *Braz J Med Biol Res.* 2004 Nov;37(11):1689-705. Epub 2004 Oct 26.
- Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. *Gastroenterology.* 2004 Nov;127(5 Suppl 1):S179-88.
- Varela M, Sala M, Llovet JM, Bruix J. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. *Aliment Pharmacol Ther.* 2003 Jun;17 Suppl 2:98-102.
- Llovet JM, Fuster J, Bruix J. Prognosis of hepatocellular carcinoma. *Hepatogastroenterology.* 2002 Jan-Feb;49(43):7-11.
- Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. *Hepatology.* 2002 Mar;35(3):519-24.
- Llovet JM, Vilana R, Bianchi L, Brú C. Radiofrequency in the treatment of hepatocellular carcinoma *Gastroenterol Hepatol.* 2001 Jun-Jul;24(6):303-11.
- NCCN Clinical Practice Guidelines in Oncology, v.3.2017 p.6-13 *Hepatology.* 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199. *Hepatol Int.* 2010 Mar 18;4(2):439-74.
- Dig Dis.* 2011;29(3):339-64. Epub 2011 Aug 9.
- RTOG Clinical research in radiation Oncology EORTC Clinical research in radiation Oncology Perez and Brady's Principles and Practice of Radiation Oncology (978-0-7817-6369-1)
- Jordi Bruix, and Morris Sherman, *HEPATOLOGY*, Vol. 53, No. 3, 2011, Management of Hepatocellular Carcinoma: An Update
- HEPATOLOGY*, Vol. 56, No. 3, 2012, Screening for Hepatocellular Carcinoma: The Rationale for the American Association for the Study of Liver Diseases Recommendations
- 盧勝男、顏毅豪、林芷芸、紀廣明、王景弘、張簡吉幸*。肝細胞癌之臨床分期。中華民國癌症醫學會雜誌(submitted, invited review article)
- Makuuchi, Masatoshi; Imamura, Hiroshi; Sugawara, Yasuhiko; Takayama, Tadatoshii. in *Surgical Treatment of Hepatocellular Carcinoma* *Oncology*; 2002; 62, ProQuest Research Library pg. 74
- S. Mizuno, K. Yamagiwa, T. Ogawa, M. Tabata, H. Yokoi, S. Isaji & S. Uemoto, Are the Results of Surgical Treatment of Hepatocellular Carcinoma Poor if the Tumor has Spontaneously Ruptured? *Scand J Gastroenterol* 2004 (6), 567-570.
- C.-N. Yen, W.-C. Lee, L.-B. Jeng, M.-F. Chen and W.-C. Yu. Spontaneous tumor rupture and prognosis in patients with hepatocellular carcinoma. *British Journal of surgery* 2002;89, 1125-1129.
- Young-Joo Jin, Jin-Woo Lee, Seoung-Wook Park, Jung Il Lee, Don Haeng Lee, Young Soo Kim, Soon Gu Cho, Yong Sun Jeon, Kun Young Lee, Seung-Ik Ahn. Survival outcome of



patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization. World J Gastroenterol 2013 July 28; 19(28): 4537-4544.

Riccardo Lencioni, Adrian M. Di Bisceglie; Peter R., Galle, Jean Francois Dufour, Tim F. Greten, Eric Raymond, Tania Roskams, Thierry De Baere, Michel Ducreux, and Vincenzo Mazzaferro. 2012. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology 2012 vol. 56 j 908–943.

器官捐贈移植作業手冊(依據 100 年 10 月 17 日「器官分配原則及相關作業規則修正會議」紀錄修正)-捐贈者基準及待移植者之絕對與相對禁忌症、適應症與各器官疾病嚴重度分級表修正草案對照表

張育霖(2012)。治療肝癌的新技術—經肝動脈釷 90 放射性栓塞。內科學誌，23：159-165

林錫銘等人。台灣肝癌醫學會 2015 肝癌診療共識指引。

Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. Available at:

Anthony B El-Khoueiry, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial 2017 ;1-11

Mahul B. Amin et al. AJCC Cancer Staging Manual 8th..2017 .Springer p45..2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut and Liver, Vol. 13, No. 3, May 2019

NCCN Guidelines Hepatocellular Carcinoma Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Reports of Practical Oncology & Radiotherapy 2015; 20(6): 417-24.

Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiat Oncol 2014; 9: 1849. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non- randomised, open-label phase 2 trial. Lancet Oncol 2018;19

NCCN Clinical Practice Guidelines in Oncology, 2025

Perez and Brady's Principles and Practice of Radiation Oncology, 7th ed, 2018

Eric K. Hansen, Handbook of Evidence-Based Radiation Oncology Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.



- Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. *The Lancet*, 391(10126), 1163–1173.
- Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. *The New England Journal of Medicine*, 359(4), 378–390.
- Llovet, J. M., et al. (2021). Hepatocellular carcinoma. *Nature Reviews Disease Primers*, 7, 6.
- IMJUDO (tremelimumab-actl) [Prescribing information]. (2022). U.S. Food and Drug Administration.
- IMFINZI (durvalumab) [Prescribing information]. (2022). U.S. Food and Drug Administration.
- Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., Rimassa, L., Sen, S., Milwee, S., El-Khoueiry, A. B. (2022). Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomized controlled trial. *BMC Cancer*, 22, 377
- Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., Pinter, M., Peña, A. M., Ikeda, M., Tai, D., Santoro, A., Pizarro, G., Chiu, C.-F., Schenker, M., He, A., Chon, H. J., ... Kudo, M. (2025).
- Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial. *The Lancet*. Advance online publication.
- Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., Pinter, M., Peña, A. M., Ikeda, M., Tai, D., Santoro, A., Pizarro, G., Chiu, C.-F., Schenker, M., He, A., Chon, H. J., ... Kudo, M. (2025).
- Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial. *The Lancet*. Advance online publication.
- Zhu, A. X., Kang, Y. K., Yen, C. J., Finn, R. S., Galle, P. R., Llovet, J. M., et al. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*, 20(2), 282–296.
- Zhu AX, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224). *Lancet Oncology*. 2018;19(7):940–952.